Minakata Y, Motegi T, Ueki J, et al. Int J Chron Obstruct Pulmon Dis. 2019;14:1789–1801.
During the publication process there was an operator error where the supplementary materials, mentioned on pages 1790 and 1793, were omitted from the manuscript. The supplementary materials are listed below:
We apologize for this oversight.
Supplementary materials
The effect of tiotropium/olodaterol combination therapy versus tiotropium monotherapy on time spent in 1.0–1.5 METs (A), ≥2.0 METs (B), and ≥3.0 METs (C) activity levels (percent change from baseline) by subgroup.
Abbreviations: BMI, body mass index; CI, confidence interval; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GOLD, global initiative for chronic obstructive pulmonary disease; IC, inspiratory capacity; METs, metabolic equivalents; mMRC, modified Medical Research Council; SGRQ, St George’s Respiratory Questionnaire; Tio, tiotropium; T+O, tiotropium/olodaterol.
The relationship between improvements in lung function and duration of 1.0–1.5 METs (A), ≥2.0 METs (B), and ≥3.0 METs (C) activity levels (percent change from baseline).
Abbreviations: CI, confidence interval; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; IC, inspiratory capacity; METs, metabolic equivalents; Tio, tiotropium; T+O, tiotropium/olodaterol.
Improvement in physical activity in patients with and without FEV1 response. FEV1 ≥100 mL was defined as the minimal clinically important difference (between tiotropium/olodaterol combination therapy and tiotropium monotherapy).
Abbreviations: FEV1, forced expiratory volume in 1 s; METs, metabolic equivalents.
Table S1.
Institutional review board list
| Institutional Review Board (location) |
|---|
| Hokkaido University Hospital (Sapporo, Hokkaido, Japan) |
| Hoshikuma Hihuka Allergy Clinic (Fukuoka, Fukuoka, Japan) |
| Iwate Medical University Hospital (Morioka, Iwate, Japan) |
| Japan Community Health care Organization Hokkaido Hospital (Sapporo, Hokkaido, Japan) |
| Japan Organization of Occupational Health and Safety Tohoku Rosai Hospital (Sendai, Miyagi, Japan) |
| Juntendo University Hospital (Bunkyo-ku, Tokyo, Japan) |
| Kagoshima University Hospital And Dental Hospital (Kagoshima, Kagoshima, Japan) |
| Kindai University Hospital (Osakasayama, Osaka, Japan) |
| Kishiwada City Hospital (Kishiwada, Osaka, Japan) |
| KKR Sapporo Medical Center (Sapporo, Hokkaido, Japan) |
| Kobe City Hospital Organization Kobe City Medical Center West Hospital (Kobe, Hyogo, Japan) |
| Kobe City Medical Center General Hospital (Kobe, Hyogo, Japan) |
| Koyasu Neurosurgical Clinic (Yokohama, Kanagawa, Japan) |
| Kurume University Hospital (Kurume, Fukuoka, Japan) |
| Kyoto University Hospital (Kyoto, Kyoto, Japan) |
| K-you Health Care Co. Kirigaoka Tsuda Hospital (Kitakyushu, Fukuoka, Japan) |
| Matsusaka City Hospital (Matsusaka, Mie, Japan) |
| National Center for Geriatrics and Gerontology (Obu, Aichi, Japan) |
| NHO Himeji Medical Center (Himeji, Hyogo, Japan) |
| NHO Ibarakihigashi National Hospital (Naka-gun, Ibaraki, Japan) |
| NHO Tenryu Hospital (Hamamatsu, Shizuoka, Japan) |
| NHO Toneyama National Hospital (Toyonaka, Osaka, Japan) |
| NHO Wakayama Hospital (Hidaka-gun, Wakayama, Japan) |
| Nihon Kokan Hospital (Kawasaki, Kanagawa, Japan) |
| Nihon Medical School (Bunkyo-ku, Tokyo, Japan) |
| Nihon University Itabashi Hospital (Itabashi-ku, Tokyo, Japan) |
| Nihonbashi Sakura Clinic (Chuo-ku, Tokyo, Japan) |
| Nishi Fukuoka Hospital (Fukuoka, Fukuoka, Japan) |
| Osaka City University Hospital (Osaka, Osaka, Japan) |
| Rakuwakai Otowa Hospital (Kyoto, Kyoto, Japan) |
| Sakaide City Hospital (Sakaide, Kagawa, Japan) |
| Shimane University Hospital (Izumo, Shimane, Japan) |
| Shinagawa East One Medical Clinic (Minato-ku, Tokyo, Japan) |
| Showa University Fujigaoka Hospital (Yokohama, Kanagawa, Japan) |
| Showa University Hospital (Shinagawa-ku, Tokyo, Japan) |
| Teine Keijinkai Clinic (Sapporo, Hokkaido, Japan) |
| Tohoku University Hospital (Sendai, Miyagi, Japan) |
| Tokyo-Eki Center-building Clinic (Chuo-ku, Tokyo, Japan) |
| Tokyo Medical University Hachioji Medical Center (Hachioji, Tokyo, Japan) |
| Tosei General Hospital (Seto, Aichi, Japan) |
| Tokushukai Group Institutional review Board (Chiyoda-ku, Tokyo, Japan) |
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
The effect of tiotropium/olodaterol combination therapy versus tiotropium monotherapy on time spent in 1.0–1.5 METs (A), ≥2.0 METs (B), and ≥3.0 METs (C) activity levels (percent change from baseline) by subgroup.
Abbreviations: BMI, body mass index; CI, confidence interval; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GOLD, global initiative for chronic obstructive pulmonary disease; IC, inspiratory capacity; METs, metabolic equivalents; mMRC, modified Medical Research Council; SGRQ, St George’s Respiratory Questionnaire; Tio, tiotropium; T+O, tiotropium/olodaterol.
The relationship between improvements in lung function and duration of 1.0–1.5 METs (A), ≥2.0 METs (B), and ≥3.0 METs (C) activity levels (percent change from baseline).
Abbreviations: CI, confidence interval; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; IC, inspiratory capacity; METs, metabolic equivalents; Tio, tiotropium; T+O, tiotropium/olodaterol.
Improvement in physical activity in patients with and without FEV1 response. FEV1 ≥100 mL was defined as the minimal clinically important difference (between tiotropium/olodaterol combination therapy and tiotropium monotherapy).
Abbreviations: FEV1, forced expiratory volume in 1 s; METs, metabolic equivalents.